The Indian Competition Appellate Tribunal (COMPAT) reverses the Indian Competition Authority’s fine of pharmaceutical companies in a bid rigging case (GlaxoSmithKline / Sanofi)

COMPAT sets aside penalty against GSK Pharmaceuticals Ltd. (GSK) and Sanofi Ltd. (Sanofi) for alleged bid-rigging in procurement of meningitis vaccine for Haj and Umrah pilgrims by Ministry of Health and Family Welfare* COMPAT by its order dated November 8, 2016, has set aside the penalty imposed by CCI on GSK and Sanofi for being guilty of acting in contravention of Section 3 (3) (d) read with Section 3(1) of the Act and imposed penalty at the rate of 3% of their turnover of last three financial years. In the Information filed by Bio-med Pvt Ltd., an indigenous manufacturer of the QMMV vaccine, it was alleged that the Union of India had abused its dominant position by incorporating restrictive and exclusionary conditions like minimum

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Vaish Associates, Advocates (New Delhi)

Quotation

Man Mohan Sharma, The Indian Competition Appellate Tribunal (COMPAT) reverses the Indian Competition Authority’s fine of pharmaceutical companies in a bid rigging case (GlaxoSmithKline / Sanofi), 8 November 2016, e-Competitions Bulletin November 2016, Art. N° 87638

Visites 22

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues